

40 Hz Auditory Steady-State Responses Predict Transition to Psychosis in Clinical-High-

Risk Participants: A MEG Study

Grent-‘t-Jong, Tineke, Ph.D.,^{1,7} Gajwani, Ruchika, Ph.D.,² Gross, Joachim, Ph.D.,^{1,3} Gumley, Andrew, I., Ph.D.,²
Krishnadas, Rajeev, M.D., Ph.D.,¹ Lawrie, Stephen M., M.D.,⁴ Schwannauer, Matthias, Ph.D.,⁵ Schultze-Lutter,
Frauke., Ph.D.⁶ & Uhlhaas, Peter J., Ph.D.^{1,7}

1. Institute of Neuroscience and Psychology, University of Glasgow, Glasgow, U.K.
2. Mental Health and Wellbeing, Institute of Health and Wellbeing, University of Glasgow,
Glasgow, U.K.
3. Institute for Biomagnetism and Biosignalanalysis, University of Muenster, Muenster,
Germany
4. Department of Psychiatry, University of Edinburgh, Edinburgh, U.K.
5. Department of Clinical Psychology, University of Edinburgh, Edinburgh, U.K.
6. Department of Psychiatry and Psychotherapy, Medical Faculty, Heinrich Heine University
Düsseldorf, Germany
7. Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany

Correspondence:

Prof. Peter J. Uhlhaas
Department of Child and Adolescent Psychiatry
Augustenburger Platz 1
Charité Universitätsmedizin
Berlin 13353
Germany
Email: peter.uhlhaas@charite.de
Tel: +49 30 450 516 193

Abstract

Objective: To examine whether 40-Hz Auditory Steady-State Responses (ASSR) in participants at clinical high-risk for psychosis predict clinical outcomes.

Method: In this study, magnetoencephalography (MEG) data were collected during a 40-Hz ASSR paradigm in 116 participants meeting clinical high-risk (CHR-P) for psychosis criteria, a clinical control group characterized by affective disorders and/or substance abuse (CHR-N: $n=38$), 32 first-episode psychosis patients (FEP, 14 antipsychotic-naïve), and 49 healthy controls. We examined 40-Hz-ASSR- source-activity in bilateral Heschl's gyrus, superior temporal gyrus, Rolandic operculum, and the thalamus. Group differences in ASSR amplitudes were tested and correlated with neuropsychological scores, psychosocial functioning, and clinical symptoms. Linear discriminant analyses was used to assess whether 40-Hz-ASSR predicts transition to psychosis and persistence of APS.

Results: Compared to controls, 40-Hz-ASSR responses in CHR-Ps were impaired in right Rolandic operculum ($d=0.41$) and right thalamus ($d=0.43$), particularly in those with combined UHR/BS symptoms and CHR-Ps who transitioned to psychosis ($n=11$). FEP-patients showed significant impairments in the right thalamus ($d=0.58$), while the CHR-N group was unaffected. Importantly, right thalamus 40-Hz-ASSRs predicted transition to psychosis (transitioned [$n=11$] vs non-transitioned [$n=105$]); classification accuracy 73.3%, $AUC=0.827$), whereas this was not the case for persistent APS (Persistent [$n=41$] vs non-Persistent [$n=37$]; classification accuracy 56.4%).

Conclusions: The current study indicates that MEG-recorded 40-Hz-ASSRs constitute a potential biomarker for predicting transition to psychosis in CHR-P participants.

Online Supplement

Clinical Follow-Up

Participants meeting CHR-P criteria were re-assessed at 3, 6, 9, 12, 18, 24, 30 and 36 months intervals to examine persistence of UHR criteria and transition to psychosis. Basic symptom criteria were only re-assessed at 24 and 36 months. For 78 CHR-P participants (67.2%), at least one follow-up assessment within year 1 was available (latest available follow-up: n=3 at 3 months; n=18 at 6 months, n=2 at 9 months, and n=55 at 12 months) and 41 CHR-Ps continued to meet APS-criteria. As of September 2020, the number of follow-up assessments conducted per time point is 41 at 3 months (2 dropouts), 106 at 6 months (10 dropouts), 70 at 9 months (2 dropouts), 87 at 12 months (10 dropouts), 82 at 18 months (10 dropouts), 57 at 24 months (12 dropouts), 16 at 30 months (6 dropouts), and 20 at 36 months (10 dropouts). Note that these numbers include all YouR Study participants, not only those that have been scanned and/or produced MEG data of high enough quality to be included in the current study.

A total of 12 CHR-P individuals (out of 124: 9.7%) have currently transitioned to psychosis. Eleven have been included in this study. For the remaining transitioned CHR-P individual, no MEG data was collected due to not meeting safety inclusion criteria for MEG recordings. Criteria for transition to psychosis were defined on the basis of the CAARMS symptom scores of sufficient duration and frequency, using symptom severity scores of 6 (maximum score) on unusual thought content, non-bizarre ideas, or disorganized speech, or a score of 5-6 (max = 6) on perceptual abnormalities. Associated frequency scores should be ranging 4-6 (max = 6), with experiences lasting longer than one week. When transition to psychosis was thus confirmed, a SCID Interview was conducted to establish the DSM-IV-category of the psychotic disorder.

Table S1. Demographic and Clinical Characteristics of CHR-P subgroups

	BS only	UHR only	UHR + BS	Statistical results ^a
Number of participants	30	31	55	
Age: years, mean (SD)	22 (4.1)	21 (4.4)	22 (4.8)	
Sex: male/female (% male)	10/20 (33.4)	5/26 (16.1)	19/36 (34.5)	
Education: years (SD)	15 (2.8)	15 (3.3)	16 (3.3)	
BACS ^b: mean (SD)				
Verbal memory	-0.19 (1.4)	-0.28 (1.2)	-0.49 (1.2)	
Digit sequencing	0.22 (1.1)	-0.28 (1.8)	-0.30 (1.5)	
Token motor	-0.95 (1.6)	-1.11 (1.2)	-0.99 (1.2)	
Verbal fluency	-0.24 (0.9)	-0.10 (1.5)	0.08(1.3)	
Symbol coding	-0.35 (1.4)	-0.71 (1.1)	-0.64 (1.0)	
Tower of London	0.01 (1.5)	-0.48 (1.5)	-0.05 (1.5)	
Composite score	-0.39 (1.3)	-0.83 (1.7)	-0.62 (1.2)	
CAARMS scores: mean (SD)				
Unusual Thought Content	1 (1.8)	1 (1.7)	2 (2.0)	
Non-bizarre Ideas	2 (1.8)	3 (1.8)	4 (1.6)	
Perceptual Abnormalities	2 (1.6)	3 (1.5)	3 (1.3)	
Disorganized Speech	1 (1.3)	1 (1.1)	2 (1.5)	
Total severity score	15 (13.5)	26 (13.7)	39 (16.5)	Group effect, $H(2) = 37.9$, $p < 0.001$
				BS < UHR: $p = 0.032$
				BS < UHR+BS: $p < 0.001$
				UHR < UHR+BS: $p = 0.004$
SPI-A severity: mean (SD)	11 (6.6)	3 (3.6)	16 (14.0)	Group effect, $H(2) = 48.3$, $p < 0.001$
				UHR < BS: $p < 0.001$
				UHR < UHR+BS: $p < 0.001$
COGDIS / COPER / both items ^c	4 / 15 / 11	-	7 / 23 / 24	
MINI categories ^d: n (%)				
Depressive/Mood disorders	19 (63)	18 (58)	38 (69)	
Anxiety disorders/PTSD/OCD	18 (60)	25 (81)	42 (76)	
Drug/alcohol abuse/dependence	10 (33)	8 (26)	21 (38)	
Eating Disorders	0 (0)	3 (10)	6 (11)	
GAF: mean (SD)	63 (13.3)	60 (13.6)	53 (13.0)	Group effect, $H(2) = 13.2$, $p = 0.001$
				BS > UHR+BS: $p = 0.002$
				UHR > UHR+BS : $p = 0.042$
GF-role: mean (SD)	7.7 (1.3)	7.7 (0.9)	7.0 (1.3)	Group effect, $H(2) = 10.4$, $p = 0.006$
				UHR+BS < BS : $p = 0.01$
GF-social: mean (SD)	7.8 (1.4)	7.5 (0.9)	7.2 (1.3)	
Transitions: n (%)	0	5 (16)	6 (11)	
Medication ^e: n (%)				
None	15 (50)	18 (58)	27 (49)	
Anti-depressants	12 (40)	9 (29)	25 (45)	
Mood stabilizers	0 (0)	1 (3)	4 (7)	
Anti-Psychotics	0 (0)	1 (3)	1 (2)	
Other	5 (17)	5 (16)	9 (16)	
MEG Trials: total included (SD)	86 (5.2)	88 (5.2)	85 (6.1)	
Task Performance				
Hit rate (% correct, SD)	99.3 (2.5)	99.7 (1.8)	99.5 (2.3)	
False Alarms (% errors, SD)	0.42 (1.11)	0.31 (0.88)	0.34 (0.58)	
Mean RT (ms, SD)	493 (145.8)	534 (132.6)	492 (116.8)	

Abbreviations: UHR, meeting CHR-P threshold on CAARMS; BS, meeting basic symptoms threshold on SPI-A; BACS, Brief Assessment of Cognition in Schizophrenia; CAARMS, Comprehensive Assessment of At Risk Mental States; COGDIS, Cognitive Disturbances criterion; COPER, Cognitive-Perceptive Basic Symptoms criterion; GAF, global assessment of functioning; GF, global functioning; MINI, Mini-International Neuropsychiatric Interview; SPI-A,

Schizophrenia Proneness Instrument, Adult version; SD, standard deviation of the mean; ms, milliseconds; RT, reaction time.

Note: Data from participants with transition to psychosis is from baseline assessment.

^a Except for 'sex' statistical testing, which are based on Chi-Square tests, all other tests are based on non-parametric Kruskal-Wallis H-tests: $\alpha=0.05$, 2-sided, adjusted for ties, post-hoc Bonferroni-corrected for multiple comparisons.

^b BACS scores for clinical groups were standardized to control group data, controlled for sex.

^c Number of items with a score of 3 or more.

^d Multiple ratings possible for comorbidities.

^e Multiple ratings possible.

Table S2. Demographic and Clinical Characteristics for APS-persistent and APS-non-persistent CHR-P participants

	APS-P	APS-NP	statistical results ^a
Number of participants	41	37	
Age: years (SD)	22 (5.1)	22 (4.4)	
Sex: male/female (%male)	14/27 (34.1)	8/29 (21.6)	
Education: years (SD)	15 (3.3)	16 (3.3)	
BACS ^b: mean (SD)			
Verbal memory	-0.45 (1.1)	-0.21 (1.2)	
Digit sequencing	-0.58 (1.8)	-0.03 (1.5)	
Token motor	-1.11 (1.3)	-1.01 (1.1)	
Verbal fluency	-0.10 (1.4)	0.09 (1.4)	
Symbol coding	-0.71 (0.9)	-0.53 (1.2)	
Tower of London	-0.08 (1.3)	-0.26 (1.6)	
Composite score	-0.81 (1.3)	-0.53 (1.5)	
CAARMS scores: mean (SD)			
Unusual Thought Content	2 (2.1)	1 (1.8)	
Non-bizarre Ideas	4 (1.4)	3 (1.8)	
Perceptual Abnormalities	3 (1.4)	3 (1.5)	
Disorganized Speech	2 (1.5)	1 (1.4)	
Total severity score	41 (16.2)	29 (14.3)	H(1) = 11.4, APS-P > APS-NT: p = 0.001
SPI-A severity: mean (SD)	13 (14.8)	9 (11.0)	H(1) = 4.9, APS-P > APS-NT: p = 0.027
CHR-P categories: n (%)			
CAARMS only	9 (22)	19 (51)	
CAARMS + SPI-A (COGDIS / COPER/ both items)	32 /78 (4 / 15 /13)	18 (49) (4 / 7 /7)	
MINI categories ^c: n (%)			
Depressive/Mood disorders	28 (68)	23 (62)	
Anxiety disorders/PTSD/OCD	32 (78)	31 (84)	
Drug/alcohol abuse/dependence	14 (34)	12 (32)	
Eating Disorders	6 (15)	3 (8)	
GAF: mean (SD)	53 (12.3)	58 (14.2)	
GF-role: mean (SD)	7.0 (1.1)	7.6 (1.0)	H(1) = 4.2, APS-P < APS-NT: p = 0.041
GF-social: mean (SD)	7.2 (1.3)	7.4 (1.1)	
Transitions (%)	9 (22.0%)	1 (2.7%)	
Medication ^d: n (%)			
None	23 (56)	18 (49)	
Anti-depressants	15 (37)	15 (41)	
Mood stabilizers	2 (5)	2 (5)	
Anti-Psychotics	1 (2)	1 (3)	
Other	5 (12)	6 (16)	
MEG Trials: total included (SD)	85 (6.4)	87 (5.1)	
Task Performance			
Hit rate (% correct, SD)	99.3 (2.6)	100.0 (0.0)	
False Alarms (% errors, SD)	0.41 (0.73)	0.26 (0.71)	
Mean RT (ms, SD)	514 (126.2)	503 (119.7)	

Abbreviations: APS, attenuated psychotic symptoms; APS-P = Persistent CAARMS group basis on the last assessment within a 12 months follow-up period; APS-NP = non-persistent CAARMS, remitted group; BACS, Brief Assessment of Cognition in Schizophrenia; CAARMS, Comprehensive Assessment of At Risk Mental States; COGDIS, Cognitive Disturbances and COPER, Cognitive-Perceptive Basic Symptoms criteria; GAF, global assessment of functioning; GF, global functioning; MINI, Mini-International Neuropsychiatric Interview; SPI-A, Schizophrenia Proneness Instrument, Adult version, SD = standard deviation of the mean, ms = milliseconds, RT = reaction time

- ^a All tests are based on non-parametric Kruskal-Wallis H-tests: $\alpha=0.05$, 2-sided, adjusted for ties.
- ^b BACS scores for clinical groups were standardized to control group data, controlled for sex.
- ^c Multiple ratings possible for comorbidities.
- ^d Multiple ratings possible.

Table S3. Demographic and Clinical Characteristics for Transitioned and Non-transitioned CHR-P participants

	CHR-P-NT	CHR-P-T	statistical results ^a
Number of participants	105	11	
Age: years (SD)	22 (4.5)	21 (5.1)	
Sex: male/female (%male)	32/73 (30.5)	2/9 (18.2)	
Education: years (SD)	15 (3.2)	15 (2.5)	
BACS ^b: mean (SD)			
Verbal memory	-0.36 (1.3)	-0.35 (0.8)	
Digit sequencing	-0.11 (1.5)	-0.64 (1.6)	
Token motor	-1.03 (1.3)	-0.81 (1.3)	
Verbal fluency	-0.02 (1.3)	-0.33 (0.8)	
Symbol coding	-0.55 (1.2)	-0.85 (0.6)	
Tower of London	-0.19 (1.5)	0.28 (1.2)	
Composite score	-0.61 (1.4)	-0.74 (0.9)	
CAARMS scores: mean (SD)			
Unusual Thought Content	2 (1.9)	3 (2.2)	
Non-bizarre Ideas	3 (1.9)	3 (1.7)	
Perceptual Abnormalities	3 (1.6)	3 (1.5)	
Disorganized Speech	1 (1.4)	2 (1.4)	
Total severity score	29 (18.0)	35 (18.5)	
SPI-A severity: mean (SD)	11 (11.7)	12 (11.2)	
CHR-P categories: n (%)			
SPI-A only (COGDIS/COPER/both items)	30 (29) (4 / 15 / 11)	-	
CAARMS only	26 (25)	5 (45)	
CAARMS + SPI-A (COGDIS / COPER/ both items)	49 (47) (6 / 22 / 21)	6 (55) (2 / 1 / 3)	
MINI categories ^c: n (%)			
Depressive/Mood disorders	64 (61)	11 (100)	
Anxiety disorders/PTSD/OCD	75 (71)	10 (91)	
Drug/alcohol abuse/dependence	32 (31)	7 (30)	
Eating Disorders	7 (7)	2 (7)	
GAF: mean (SD)	58 (14.2)	51 (6.2)	H(1) = 4.0, CHR-P-T < CHR-P-NT: p = 0.045
GF-role: mean (SD)	7.4 (1.2)	7.1 (1.4)	
GF-social: mean (SD)	7.5 (1.3)	6.7 (1.0)	H(1) = 5.7, CHR-P-T < CHR-P-NT: p = 0.017
Medication ^d: n (%)			
None	54	6	
Anti-depressants	43	3	
Mood stabilizers	5	0	
Anti-Psychotics	2	0	
Other (Unknown)	17 (0)	2 (0)	
MEG Trials: total included (SD)	86 (5.6)	84 (7.3)	
Task Performance			
Hit rate (% correct, SD)	99.5 (2.1)	99.1 (3.0)	
False Alarms (% errors, SD)	0.33 (0.83)	0.54 (0.68)	
Mean RT (ms, SD)	496 (125.8)	574 (146.0)	
SCID diagnosis for CHR-P-T	Schizophrenia, Major Depressive Disorder (n = 1), Schizoaffective Disorder, Bipolar-I, Major Depressive Disorder (n = 2), Schizoaffective Disorder, Major Depressive Disorder (n = 2), Delusional Disorder (n = 1), Delusional Disorder, Major Depressive Disorder, Bipolar I (n = 1), Psychotic Disorder NOS (n = 2), Bipolar-II with psychotic features, Major Depressive Disorder (n = 1), and 1 case unknown (no SCID data available).		

Abbreviations: CHR-P-NT = non-transitioned CHR-P participants; CHR-P-T = transitioned CHR-P participants; BACS, Brief Assessment of Cognition in Schizophrenia; CAARMS, Comprehensive Assessment of At Risk Mental States; COGDIS, Cognitive Disturbances and COPER, Cognitive-Perceptive Basic Symptoms criteria; GAF, global assessment of functioning; GF, global functioning; MINI, Mini-International, N/A, Not applicable Neuropsychiatric Interview; SPI-A, Schizophrenia Proneness Instrument, Adult version, SD = standard deviation of the mean, ms = milliseconds, RT = reaction time


^a All tests are based on non-parametric Kruskal-Wallis H-tests: alpha=0.05, 2-sided, adjusted for ties.

^b BACS scores for clinical groups were standardized to control group data, controlled for sex.

^c Multiple ratings possible for comorbidities.


^d Multiple ratings possible.

Figure S1. Baseline 40-Hz activity



Cumming Estimation Plots of RROL (left panel) and RTHA (right panel) data, tested for baseline (-500-0 ms) 40-Hz activity in the contrast between the three main groups (CHR-N, CHR-P, and FEP) compared to healthy controls. No significant effects were found. Abbrev.: HC = healthy controls, CHR-N = clinical-high risk negative, CHR-P = clinical-high-risk positive, FEP = First-Episode-Psychosis group.


Figure S2. 40-Hz ASSR activity in subcortical regions around the thalamus



Cumming Estimation Plots for 6 subcortical regions surrounding the left and right THA, for the contrast between data from the three main groups (CHR-N, CHR-P, and FEP), compared to healthy controls.. None of these control subcortical regions showed significant group differences, in contrast to the impairments seen in RTHA, not LTHA, as shown in main text Figure 2. Abbrev.: HC

= healthy controls, CHR-N = clinical-high risk negative, CHR-P = clinical-high-risk positive, FEP = First-Episode-Psychosis group,
 PUT = putamen, CAU = caudate, PAL = pallidum.

Figure S3. Effect of medication on 40-Hz ASSR activity in FEP group



Cumming Estimation Plots of RROL (left panel) and RTHA (two right panels) data, tested for 40-Hz activity in the contrast between the two subgroups of FEP patients (based on medication status: 14 without [FEP-NM] and 18 with [FEP-M] anti-psychotic medication) versus healthy controls (left two panels) and against each other (most right panel). An * indicates significant differences with $p < 0.05$. Abbrev.: HC = healthy controls, FEP-NM = non-medicated FEP, FEP-M = Medicated FEP.